Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.

Abstract

INTRODUCTION Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme. PATIENTS AND METHODS Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy. RESULTS Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay. CONCLUSIONS Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.

DOI: 10.1016/j.ejca.2014.03.001

Cite this paper

@article{Khan2014AfatinibUI, title={Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.}, author={Faisel Khan and Christian H. Ottensmeier and Sanjay Popat and Devender Dua and Nicholas Dorey and Spencer Ellis and Margaret Szab{\'o} and Sushil Upadhyay and Raffaele Califano and Stephen Chan and Linda Lee and Clinton W. Ali and Marianne Nicolson and Andrew Tom Bates and Matthew F Button and Avi Chaudhuri and Paula M Mulvenna and Heather Shaw and Sarah J. Danson}, journal={European journal of cancer}, year={2014}, volume={50 10}, pages={1717-21} }